Phreesia, Inc. (NYSE:PHR) CEO Sells $272,412.66 in Stock

Phreesia, Inc. (NYSE:PHR) CEO Chaim Indig sold 12,043 shares of the company’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $22.62, for a total value of $272,412.66. Following the completion of the sale, the chief executive officer now owns 1,225,397 shares of the company’s stock, valued at $27,718,480.14. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Chaim Indig also recently made the following trade(s):

• On Tuesday, January 16th, Chaim Indig sold 3,586 shares of Phreesia stock. The stock was sold at an average price of $24.55, for a total value of $88,036.30.

Phreesia Trading Up 2.1 %

Shares of NYSE:PHR opened at $23.80 on Friday. The business’s 50-day moving average is $24.76 and its 200 day moving average is $21.09. Phreesia, Inc. has a 1 year low of $12.05 and a 1 year high of $34.98. The firm has a market capitalization of $1.34 billion, a P/E ratio of -9.44 and a beta of 0.92. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.78 and a quick ratio of 1.78.

Phreesia (NYSE:PHR) last announced its quarterly earnings data on Thursday, March 14th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.02. The business had revenue of $95.00 million for the quarter, compared to analyst estimates of $93.52 million. Phreesia had a negative return on equity of 53.33% and a negative net margin of 38.42%. The company’s revenue was up 24.0% on a year-over-year basis. During the same period in the prior year, the company earned ($0.72) earnings per share. On average, research analysts predict that Phreesia, Inc. will post -1.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on PHR. Stephens reiterated an “overweight” rating and issued a $28.00 target price on shares of Phreesia in a report on Friday, March 22nd. Barclays assumed coverage on Phreesia in a research report on Wednesday, January 3rd. They issued an “overweight” rating and a $29.00 price target for the company. Truist Financial assumed coverage on Phreesia in a research report on Monday, February 26th. They issued a “buy” rating and a $35.00 price target for the company. Needham & Company LLC reissued a “buy” rating and issued a $29.00 price target on shares of Phreesia in a research report on Friday, March 15th. Finally, Raymond James reissued an “outperform” rating and issued a $30.00 price target (up from $25.00) on shares of Phreesia in a research report on Friday, March 15th. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, Phreesia has an average rating of “Moderate Buy” and a consensus target price of $31.62.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. CI Investments Inc. increased its holdings in shares of Phreesia by 6.6% in the third quarter. CI Investments Inc. now owns 477,265 shares of the company’s stock valued at $8,915,000 after purchasing an additional 29,500 shares during the period. Schroder Investment Management Group purchased a new position in Phreesia during the third quarter worth approximately $6,514,000. TimesSquare Capital Management LLC boosted its position in Phreesia by 7.8% during the third quarter. TimesSquare Capital Management LLC now owns 774,079 shares of the company’s stock worth $14,460,000 after purchasing an additional 55,793 shares in the last quarter. Lazard Asset Management LLC boosted its position in Phreesia by 58.6% during the third quarter. Lazard Asset Management LLC now owns 424,047 shares of the company’s stock worth $7,921,000 after purchasing an additional 156,711 shares in the last quarter. Finally, Trust Point Inc. purchased a new position in Phreesia during the fourth quarter worth approximately $239,000. 92.10% of the stock is owned by institutional investors and hedge funds.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.